Honczarenko Marek 4

What Happened
Marek Honczarenko, EVP and Chief Scientific Officer of Keenova Therapeutics plc, received a grant of 58,434 restricted stock units (RSUs) on February 25, 2026. The award is recorded at $0.00 per unit (no cash paid); the RSUs are derivative awards that will convert into ordinary shares upon vesting.

Key Details

• Transaction date: 2026-02-25; Transaction type: Award/Grant (code A). Price reported: $0.00 per RSU.
• Quantity: 58,434 RSUs. Total cash paid: $0.00 (award grant).
• Vesting: RSUs will settle one ordinary share per RSU (Footnote F1). They vest ratably on each of the first three anniversaries of February 25, 2027 (Footnote F2).
• Shares owned after transaction: not reported on this Form 4.
• Filing status: Form 4 filed 2026-02-26 (timely); filing also serves as notice to the issuer under Part V of the Companies Act 2014 (per remarks).

Context
RSU grants are compensation awards, not open-market purchases or sales; they do not represent immediately tradable shares until they vest and are settled. There is no indication here of immediate sale or cashless exercise; tax withholding or other post-vesting actions are not detailed in this filing.